HOME > 業績集

業績集

子宮頸がん委員会

  1. Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation.
    Matsuo K, Shimada M, Aoki Y, Sakamoto M, Takeshima N, Fujiwara H, Matsumoto T, Mikami M, Sugiyama T.
    Int J Cancer. 2017 May 19. doi: 10.1002/ijc.30793.
    link
  2. Human Papillomavirus Test for Triage of Japanese Women With Low-Grade Squamous Intraepithelial Lesions.
    Iwata T, Hasegawa T, Ochiai K, Takizawa K, Umezawa S, Kuramoto H, Ohmura M, Kubushiro K, Arai H, Sakamoto M, Motoyama T, Watanabe K, Aoki D.
    Reprod Sci. 2015 Jun 19. pii: 1933719115589408.
    link
  3. シリーズで学ぶ最新知識 子宮頸がん臨床試験の最前線(1)GCIG 2014 Cervical Cancer Brainstorming Meeting in Melbourneの報告(1)
    寒河江 悟. 戸板 孝文. 三上 幹男 他.
    産婦人科の実際.64(4):2015.4
    link
  4. Surgical Principles for Managing Stage IB2, IIA2, and IIB Uterine Cervical Cancer (Bulky Tumors) in Japan: A Survey of the Japanese Gynecologic Oncology Group.
    Mikami M, Aoki Y, Sakamoto M, Shimada M, Takeshima N, Fujiwara H, Matsumoto T, Kita T, Takizawa K; Disease Committee of Uterine Cervical and Vulvar Cancer, Japanese Gynecologic Oncology Group.
    International Journal of Gynecological Cancer. 24(7):1333-40, 2014 Sep.
    link
  5. Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100:a JGOG study
    Sugiyama T, Fujiwara K, Ohashi Y, Yokota H, Hatae M, Ohno T, Nagai Y, Mitsuhashi N, Ochiai K, Noda K.
    Annals of Oncology. 2014 May;25(5):1011-7
    link
  6. Current surgical principle for uterine cervical cancer of stages Ia2, Ib1, and IIa1 in Japan: a survey of the Japanese Gynecologic Oncology Group.
    Mikami M. Aoki Y. Sakamoto M. Shimada M. Takeshima N. Fujiwara H. Matsumoto T. Kita T. Takizawa K.
    International Journal of Gynecological Cancer. 2013; 23(9): 1655-60; quiz 1661-2.
    link
  7. Feasibility and Acute Toxicity of Concurrent Chemoradiotherapy (CCRT) With High-Dose Rate Intracavitary Brachytherapy (HDR-ICBT) and 40-mg/m2 Weekly Cisplatin for Japanese Patients With Cervical Cancer: Results of a Multi-Institutional Phase 2 Study (JGOG1066).
    Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, Oguchi M, Mikami M, Takizawa K; Cervical Cancer (Vulva Cancer) Committee of the Japanese Gynecologic Oncology Group (JGOG).
    Int J Gynecol Cancer. 2012; 22: 1420-26.
    link
  8. Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065).
    Yamaguchi S, Nishimura R, Yaegashi N, Kiguchi K, Sugiyama T, Kita T, Kubushiro K, Kokawa K, Hiura M, Mizutani K, Yamamoto K, Takizawa K.
    Oncol Rep. 2012; 28: 487-93.
    link
  9. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: Efficacy and toxicity of a low cumulative radiation dose schedule.
    Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, Oguchi M, Mikami M, Takizawa K; Cervical Cancer (Vulva Cancer) Committee of the Japanese Gynecologic Oncology Group (JGOG).
    Gynecol Oncol. 2012; 126: 211-6.
    link
  10. Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer.
    Toita T, Kato S, Ishikura S, Tsujino K, Kodaira T, Uno T, Hatano K, Sakurai H, Niibe Y, Kazumoto T, Nishimura T, Kitagawa R, Fukutani M, Oguchi M, Umayahara K, Hirashima Y, Aoki Y, Takizawa K; and Disease Committee of Radiation Oncology, Japanese Gynecologic Oncology Group.
    Int J Clin Oncol. 2011; 16 : 379-86.
    link
  11. Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study.
    Yamamoto K, Kokawa K, Umesaki N, Nishimura R, Hasegawa K, Konishi I, Saji F, Nishida M, Noguchi H, Takizawa K.
    Oncol Rep. 2009; 21: 1005-9.
    link
  12. Phase I study of irinotecan combined with mitomycin- C and 5-fluorouracil for gynecological malignancies; The JGOG Study.
    Kokawa K, Umesaki N, Yamamoto K, Takizawa K, Konishi I, Hasegawa K; Japan Gynecologic Oncology Group.
    Anticancer Res. 2008; 28: 2933-9.
    link
  13. Adjuvant oral 5-fluorouracil for cervical cancer: Japanese Gynecologic Oncology Group report.
    Yamamoto K, Izumi R, Hasegawa K, Nakajima H, Ohashi K, Kudo R, Okuda H, Takahashi T, Origasa H, Sugimori H.
    Int J Oncol. 2004; 24: 1175-9.
    link
  14. Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study.
    Umesaki N, Fujii T, Nishimura R, Tanaka T, Nishida M, Fushiki H, Takizawa K, Yamamoto K, Hasegawa K, Izumi R; Japan Gynecologic Oncology Group.
    Gynecol Oncol. 2004; 95: 127-32.
    link
  15. 進行・再発子宮頸癌に対するBOMP療法の効果(子宮頸がん第5次特定研究DS-1).
    梅咲直彦、野口浩、伏木弘、西田正人、奥田博之、滝澤憲、宇田川康博、山本嘉一郎、長谷川和男、泉陸一.
    第18回婦人科がん化学療法共同研究会記録集 23-7, 2001
    pdf
  16. 進行および再発子宮頸部腺癌に対するMEP療法の効果.
    梅咲直彦、泉陸一、宇田川康博、奥田博之、河野一郎、杉森甫、滝澤憲、西田正人、長谷川和男、伏木弘、山本嘉一郎、野田起一郎、田中哲二.
    Oncol Chemother.182-6, 2000
    pdf
  17. Cervical adenocarcinoma, a novel combination chemotherapy with mitomycin C, etoposide, and cisplatin for advanced or recurrent disease.
    Umesaki N, Izumi R, Fushiki H, Hasegawa K, Kono I, Nishida M, Noguchi H, Okuda H, Sugimori H, Takizawa K, Udagawa Y, Yamamoto K, Tanaka T, Noda K.
    Gynecol Oncol.1999; 75: 142-4.
    link
  18. Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan.
    Ikeda Y, Furusawa A, Kitagawa R, Tokinaga A, Ito F, Ukita M, Nomura H, Yamagami W, Tanabe H, Mikami M, Takeshima N, Yaegashi N.
    J Gynecol Oncol. 2016 May;27(3):e29.
    link

子宮体がん委員会

  1. Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group.
    Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T.
    Gynecol Oncol. 2016 Apr 14. pii: S0090-8258(16)30105-6.
    link
  2. How do Japanese gynecologists view hormone replacement therapy for survivors of endometrial cancer? Japanese Gynecologic Oncology Group (JGOG) survey.
    Yokoyama Y, Ito K, Takamatsu K, Takehara K, Nakanishi T, Harano K, Watari H, Susumu N, Aoki D, Saito T.
    Int J Clin Oncol. 2015 Oct;20(5):997-1004. doi: 10.1007/s10147-015-0808-5. Epub 2015 Mar 6.
    link
  3. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
    Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T.
    Int J Clin Oncol. 2015 Jun 18.
    link
  4. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).
    Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, Jobo T, Hatae M, Hiura M, Yaegashi N.
    Ann Oncol. 2011; 22: 636-42.
    link
  5. Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group(JGOG2044s).
    Watanabe Y, Kitagawa R, Aoki D, Takeuchi S, Sagae S, Sakuragi N, Yaegashi N; Disease Committee of Uterine Endometrial Cancer, Japanese Gynecologic Oncology Group.
    Gynecol Oncol. 2009; 115: 456-9.
    link
  6. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
    Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, Kudo R; Japanese Gynecologic Oncology Group.
    Gynecol Oncol. 2008; 108: 226-33.
    link
  7. Status of surgical treatment procedures for endometrial cancer in Japan: results of a Japanese Gynecologic Oncology Group survey.(JGOG2045s)
    Watanabe Y, Aoki D, Kitagawa R, Takeuchi S, Sagae S, Sakuragi N, Yaegashi N; Disease Committee of Uterine Endometrial Cancer, Japanese Gynecologic Oncology Group.
    Gynecol Oncol. 2007; 105: 325-8.
    link
  8. 子宮体がん化学療法第三次研究の最終解析成績.
    佐藤信二、野澤志朗、宇田川康博、丹羽憲司、寒河江悟、工藤隆一、蔵本博行、西谷巖.
    第17回婦人科がん化学療法共同研究会記録集22-7, 2000
    pdf
  9. 子宮体がん化学療法第2次研究の最終解析成績.
    佐藤信二、矢嶋聰、野澤志朗、宇田川康博、寺島芳輝、西谷巖、小澤満、工藤隆一、蔵本博行、岡田弘二.
    Oncol Chemother.12(Suppl): 14-20, 1996
    pdf
  10. 子宮体癌に対する補助化学療法および寛解導入療法 子宮体がん化学療法第一次研究.
    佐藤信二、矢嶋聰、野澤志朗、宇田川康博、寺島芳輝、西谷巖、小澤満、工藤隆一、蔵本博行、岡田弘二.
    Oncol Chemother.11: 188-197, 1995
    pdf

卵巣がん委員会

  1. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
    Sugiyama T, Okamoto A, Enomoto T, Hamano T, Aotani E, Terao Y, Suzuki N, Mikami M, Yaegashi N, Kato K, Yoshikawa H, Yokoyama Y, Tanabe H, Nishino K, Nomura H, Kim JW, Kim BG, Pignata S, Alexandre J, Green J, Isonishi S, Terauchi F, Fujiwara K, Aoki D.
    J Clin Oncol. 2016 Aug 20;34(24):2881-7. doi: 10.1200/JCO.2016.66.9010. Epub 2016 Jul 11.
    link pdf
  2. Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016).
    Harano K. Terauchi F. Katsumata N. Takahashi F. Yasuda M. Takakura S. Takano M. Yamamoto Y. Sugiyama T..
    Annals of Oncology. 2014; 25(1): 251-7.
    link
  3. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
    Katsumata N. Yasuda M. Isonishi S. Takahashi F. Michimae H. Kimura E. Aoki D. Jobo T. Kodama S. Terauchi F. Sugiyama T. Ochiai K.
    Lancet Oncology. 2013; 14(10): 1020-6.
    link
  4. Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
    Ushijima K. Kamura T. Tamura K. Kuzuya K. Sugiyama T. Noda K. Ochiai K.
    International Journal of Clinical Oncology. 2013; 18(1): 126-31.
    link
  5. Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.
    Kumagai S, Sugiyama T, Shoji T, Michimae H, Katsumata N, Aoki D, Terauchi F, Jobo T, Ochiai K, Yasuda M.
    Int J Gynecol Cancer. 2011; 21: 1585-91.
    link
  6. Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
    Ushijima K, Kamura T, Tamura K, Kuzuya K, Sugiyama T, Noda K, Ochiai K.
    Int J Clin Oncol. 2011 Nov 30. [Epub ahead of print]
    pdf
  7. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
    Takakura S, Takano M, Takahashi F, Saito T, Aoki D, Inaba N, Noda K, Sugiyama T, Ochiai K; Japanese Gynecologic Oncology Group.
    Int J Gynecol Cancer. 2010; 20: 240-7.
    pdf
  8. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
    Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K; Japanese Gynecologic Oncology Group.
    Lancet. 2009; 374: 1331-8.
    pdf
  9. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
    Katsumata N, Fujiwara Y, Kamura T, Nakanishi T, Hatae M, Aoki D, Tanaka K, Tsuda H, Kamiura S, Takehara K, Sugiyama T, Kigawa J, Fujiwara K, Ochiai K, Ishida R, Inagaki M, Noda K.
    Jpn J Clin Oncol. 2008; 38: 777-85.
    pdf
  10. RANDOMIZED TRIAL ON ADJUVANT IV CHEMOTHERAPY CDDP + CPA VERSUS PO CHEMOTHERAPY CPA FOR STAGE IA OVARIAN CANCER BY THE JAPANESE GYNECOLOGIC ONCOLOGY AND CHEMOTHERAPY STUDY GROUP (Meeting abstract).
    Hatae M, Onishi Y, Noda K, Yakushiji M, Ozaki K, Ochiai K, Kuzuya K, Takahashi T, Tateno M, Yoshikawa H, Nishida T.
    1998 ASCO Annual Meeting Abstract No: 1412
    pdf

 

このページの先頭へ